Enhanced Efficacy of a Cell-Based Influenza Vaccine

The superior effectiveness of the cell-based quadrivalent influenza vaccine (QIVc) compared to the traditional egg-based vaccine (QIVe) has been demonstrated in a real-world evidence (RWE) study conducted over three flu seasons (2017–2020) in the U.S. The study, led by CSL Seqirus, and published in Open Forum Infectious Diseases, included over 99,600 participants across the three seasons. The authors demonstrated that QIVc consistently achieved at least a 10% higher vaccine effectiveness when preventing test-confirmed influenza. Comparing the vaccine effectiveness between each season, the relative vaccine effectiveness (rVE) of QIVc over QIVe was 14.8% in 2017–18, 12.5% in 2018–19, and 10% in 2019–20. These findings demonstrate the benefits of using cell-based technologies, of which allow for an exact match to the World Health Organization’s identified influenza strains, and could improve future vaccine effectiveness. CSL Seqirus highlighted these findings as a testament to the value of RWE in assessing vaccine performance and improving community health outcomes. The study also illustrates the limitations of retrospective analyses, suggesting a robust framework for understanding vaccine efficacy through RWE.

To read more, click here.

[Source: PR Newswire, May 2 2024]